Sino Biological launches 2026-2027 Northern Hemisphere influenza vaccine strain antigens

Sanaregen receives FDA clearance for retinal degeneration clinical trial

Lynk Pharmaceuticals reveals positive topline results from zemprocitinib Phase III clinical trial

ReviR Therapeutics doses first participant in First-in-Human Phase 1 clinical trial of RTX-117

Ono Pharmaceutical expands multi-target research collaboration with Congruence Therapeutics

United Therapeutics' ralinepag reduces risk of clinical worsening in pivotal PAH study

Genentech's fenebrutinib meets primary endpoint in pivotal Phase III study for multiple sclerosis

ValiRx establishes animal health subsidiary to target veterinary oncology market

FDA accepts rusfertide NDA and grants priority review for polycythemia vera

UAE approves PYRUKYND for treatment of thalassaemia

Sanofi's rilzabrutinib receives orphan drug designation in Japan for IgG4-related disease

Genflow Biosciences receives first EUR336,467 tranche of EUR4m Wallonia grant

Novacyt completes acquisition of Southern Cross Diagnostics

Eli Lilly's Olumiant (baricitinib) receives positive European regulatory opinion for approval to treat adolescents with severe alopecia areata

Atrium Therapeutics launches as newly independent, publicly traded company